Latest news with #Dexcom
Time of India
9 hours ago
- Business
- Time of India
PM highlights swift wars, local defence platforms
Prime Minister Narendra Modi on Wednesday highlighted the changing nature of warfare in his first council of ministers meeting following Operation Sindoor , stating that actions can now be completed within minutes. He remarked that the world has witnessed India's growing capabilities. Modi referred to Operation Sindoor during the meeting, which lasted over four hours. He emphasised the effectiveness of indigenous weapons used during the operation and stressed the government's focus on promoting Make in India defence platforms. He also urged ministers to spend at least one night in aspirational blocks across the country to gain a better understanding of local issues. Additionally, Modi encouraged flexibility regarding office space as ministries relocate to new Central Secretariat buildings, and advised ministers to set higher goals rather than compare current achievements with those of previous governments. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Discover Effortless Glucose Monitoring: Request a Free Trial Dexcom Click Here The meeting featured presentations by the Health Secretary on obesity and reducing edible oil consumption, the Jal Shakti Secretary on water conservation, the Commerce Secretary on trade, and the Cabinet Secretary. Modi called for infrastructure and manufacturing projects to meet global standards. He urged ministers to work at full pace and highlight five key successes of their ministries during the Modi government's third-term first anniversary celebrations beginning 9 June. Live Events
Yahoo
5 days ago
- Business
- Yahoo
Goldman Sachs initiates coverage of medtech stocks Insulet and Dexcom at Buy
-- Goldman Sachs has initiated coverage of diabetes technology stocks Insulet (NASDAQ:PODD) and Dexcom (NASDAQ:DXCM) with Buy ratings, citing strong long-term growth prospects in both the insulin delivery and continuous glucose monitoring (CGM) markets. In a research note, Goldman Sachs described the diabetes technology market as 'at a crossroads,' with growth shifting from its core Type 1 diabetes patient base toward the broader Type 2 diabetes population and even consumer markets. 'We see Insulet as well positioned to accelerate market share capture given its unique form factor (patch vs durable), pharmacy access, and Type 2 indication,' the analysts wrote. They added that the company's valuation sits 'at the high end of growth medtech.' Dexcom also earned a Buy rating, with Goldman noting that while the stock has underperformed over the past year, falling 43% relative to the S&P 500, 'we view forward estimates as appropriately re-calibrated.' The analysts expect 'upside to 2025 top-line expectations,' though they acknowledged caution on gross margins due to 'supply-related issues in 1H.' Still, they believe 'more steady execution should unlock share value from here.' Goldman sees the insulin pump market growing 11.4% annually in volume and 12.7% in dollars through 2028, driven by further penetration into the Type 1 population and expansion into the Type 2 multiple daily injector segment. 'We expect patch pump technology to become the primary form factor for insulin pumps,' the firm said, projecting a shift from 30% patch pump share in 2024 to 40% by 2028. Goldman also initiated coverage on Beta Bionics (BBNX) with a Neutral rating and maintained existing ratings on Abbott (ABT, Buy) and Tandem (TNDM, Neutral). Related articles Goldman Sachs initiates coverage of medtech stocks Insulet and Dexcom at Buy AGCO downgraded as Citi says risk/reward now more balanced Sanofi, Regeneron shares nosedive after mixed Itepekimab results Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 days ago
- Business
- Yahoo
Continuous Glucose Monitoring Devices Market Size expected to reach US$ 32.97 billion by 2031, Increasing Demand for Effective Diabetes Management Propels Growth
The Continuous Glucose Monitoring (CGM) devices market, valued at $12.63 billion in 2024 and projected to reach $32.97 billion by 2031, is growing at a 12.6% CAGR, driven by rising diabetes prevalence, home-based care, and technological advancements, with key players including Dexcom, Abbott, Medtronic, and Senseonics leading innovation in real-time, wearable, and non-invasive monitoring solutions. US & Canada, May 30, 2025 (GLOBE NEWSWIRE) -- According to a new comprehensive report from The Insight Partners, the global continuous glucose monitoring devices market is observing significant growth owing to the increasing demand for effective diabetes management and the growing use of OTC products. The report runs an in-depth analysis of market trends, key players, and future opportunities. In general, the continuous glucose monitoring devices market comprises a vast array of products and services that are expected to register strength in the coming years. To explore the valuable insights in the Continuous Glucose Monitoring Device Market report, you can easily download a sample PDF of the report - Overview of Report Findings Market Growth: The continuous glucose monitoring devices market is expected to reach US$ 32.97 billion by 2031 from US$ 12.63 billion in 2024, at a CAGR of 12.6% during the forecast period. Continuous glucose monitoring devices (CGMD) represent the most advanced technology for managing diabetes manually, featuring components such as sensors, transmitters, and monitors. These devices offer real-time updates on blood sugar levels. This information allows individuals to adjust their dietary choices or insulin doses as recommended by their healthcare provider. By providing real-time data, these devices help reduce the risk of hypoglycemia and hyperglycemia in those living with diabetes. Increasing Need for Effective Diabetes Management: Diabetes, especially type 2, is a growing global concern, with countries such as India seeing a significant increase. As per the International Diabetes Federation (IDF) Diabetes Atlas, ~10.5% of adults globally aged 20–79 years had diabetes in 2021. This number is projected to rise to 12.2% by 2045. According to the World Health Organization (WHO), ~77 million people aged 18 and older in India were living with diabetes, while ~25 million were considered pre-diabetic in 2022. This increasing incidence underscores the urgent need for proactive products and tools for advanced, user-friendly monitoring, such as CGM devices, to address the issue. CGM systems offer real-time insights into glucose levels, allowing users to make quick decisions about diet, exercise, and medication. This ongoing data helps achieve better blood sugar control, lower HbA1c levels, and prevent hypoglycemia, organ damage, etc. By detecting glucose fluctuations early—often before symptoms arise—CGM empowers patients and healthcare providers to intervene effectively. Surging Use of OTC Products: The availability of over-the-counter (OTC) CGM devices has greatly increased market growth by making glucose monitoring more accessible and affordable. Since these devices don't require prescriptions, individuals can easily purchase them from pharmacies, online retailers, or supermarkets. This convenience has led to widespread use among people with diabetes, those at risk, and health-conscious individuals looking to monitor their well-being. In March 2024, the US Food and Drug Administration (FDA) accepted the first OTC continuous glucose monitor (CGM) for marketing. The Dexcom Stelo Glucose Biosensor System is an integrated CGM (iCGM) designed for individuals aged 18 and older who do not use insulin. This includes people with diabetes managing their condition with oral medications, as well as those without diabetes who want to understand the effect of diet and exercise on blood sugar levels. Geographical Insights: In 2024, North America led the market with a substantial revenue share, followed by Europe and APAC. Asia Pacific is expected to register the highest CAGR during the forecast period. For Detailed Continuous Glucose Monitoring Device Market Insights, Visit: Market Segmentation Based on product, the continuous glucose monitoring devices market is segmented into sensors, transmitters, and receivers. The sensors segment held the largest share of the continuous glucose monitoring devices market in 2024. Based on testing sites, the continuous glucose monitoring devices market is bifurcated into fingertip testing and alternate site testing. The fingertip testing segment held a larger share of the continuous glucose monitoring devices market in 2024. In terms of application, the continuous glucose monitoring devices market is bifurcated into type-1 diabetes and type-2 diabetes. The type-2 diabetes segment held a larger share of the continuous glucose monitoring devices market in 2024. In terms of end user, the continuous glucose monitoring devices market is bifurcated into hospitals and clinics and self/home care. The hospitals and clinics segment held a larger share of the continuous glucose monitoring devices market in 2024. The continuous glucose monitoring devices market is segmented into five major regions: North America, Europe, APAC, Middle East and Africa, and South and Central America. Competitive Strategy and Development Key Players: A few major companies operating in the continuous glucose monitoring devices market include B. Braun SE, F. Hoffmann-La-Roche Ltd, LifeScan Inc, Medtronic, Abbott Laboratories, Ypsomed Holding AG, Sensionics, Nipro Corp, GE Healthcare, and Novo Nordisk A/S. Trending Topics: Advanced Continuous Glucose Monitoring Devices, AI in Continuous Glucose Monitoring Devices, Type-2 Diabetes Management, and OTC Devices for Continuous Glucose Management, among others. Stay Updated on The Latest Continuous Glucose Monitoring Device Market Trends: Global Headlines on Continuous Glucose Monitoring Devices Philips-Medisize announced a partnership with GlucoModic to commercialize a proprietary non-invasive and wearable device. This partnership aims to develop a solution that is needle-free, accurate, and more affordable for diabetic patient to monitor their blood glucose levels. Medtronic received CE Mark approval for the "MiniMed 780G system" with the Simplera Sync, a disposable all-in-one Continuous Glucose Monitoring device that requires no finger pricks or overtaping. This new product will be available in Europe, with a phased commercial launch planned for Spring 2024. Dexcom launched a new Continuous Glucose Monitoring device, the "Dexcom G7." This device is the smallest and most accurate Continuous Glucose Monitoring option connected to the t:slim X2 insulin pump. The Dexcom G7 has the fastest sensor warm-up time at just 30 minutes and, along with the Dexcom G6, is the only Continuous Glucose Monitoring system capable of providing alerts without the need for finger pricks. Roche received the CE Mark for its AI-enabled continuous glucose monitoring solution, the Accu-Chek SmartGuide CGM. This device offers accurate real-time glucose readings for 14 days, helping adults with type 1 and type 2 diabetes with flexible insulin therapy. Purchase Premium Copy of Global Continuous Glucose Monitoring Device Market Size and Growth Report (2020-2031) at: Conclusion The growing prevalence of diabetes and rising use of OTC products for self-management drive the continuous glucose monitoring devices market growth. The utilization of Continuous Glucose Monitoring (CGM) systems has broadened its scope beyond insulin-dependent individuals to encompass those with type 2 diabetes, as well as health-conscious non-diabetics. This expansion is attributed to technological advancements such as smartphone integration, artificial intelligence, and non-invasive sensor technology. Adoption barriers are being removed by increased insurance coverage, OTC access, and other regulatory reforms, especially in large countries, including the US and Europe. Due to increased accessibility, cost, and user empowerment, the shift to OTC availability has democratized glucose monitoring, greatly expanding the industry and fostering long-term market growth. Talk to Us Directly: Related Reports: About Us: The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials. Contact Us: If you have any queries about this report or if you would like further information, please contact us: Contact Person: Ankit Mathur E-mail: Phone: +1-646-491-9876 Home - in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 days ago
- Business
- Yahoo
Kalorama Information Releases 12th Edition of Global Point-of-Care Diagnostics Market Report, Forecasting Steady Growth Through 2029 for $36 Billion POC Market
ARLINGTON, Va., May 29, 2025 /PRNewswire/ -- The global point-of-care (POC) diagnostics market surpassed $36 billion in 2024, according to the newly released "Worldwide Market for Point-of-Care Diagnostic Tests, 12th Edition" by Kalorama Information, a leading publisher of medical market research. The comprehensive study forecasts sustained market expansion through 2029, driven by an aging population, rising disease incidence, and rapid technological advancements. "POC testing is no longer a fringe segment—it is a central pillar of modern diagnostics," said Melissa Elder, Senior Analyst at Kalorama Information. "We see industry leaders like Abbott, Dexcom, Roche, Danaher, and Exact Sciences innovating aggressively, with POC solutions spanning blood gases, infectious disease, colon cancer, glucose monitoring, and more." Key Insights from the Report: $36 Billion in Global Revenues in 2024: Driven by physician offices, clinics, and mobile care platforms, the global POC market is on a mid-single-digit compound annual growth rate (CAGR) trajectory through 2029. High-Impact Segments: Growth areas include oncology, stroke, dementia, cardiac markers, and glucose monitoring—particularly fueled by continuous glucose monitoring (CGM) adoption. Technology Is Reshaping POC: Advancements in CRISPR virus detection, biosensors, lab-on-a-chip, and AI-assisted testing are transforming point-of-care capabilities. Molecular POC Diagnostics Are Expanding: With roots in pandemic response, these rapid and sensitive tests now serve emergency care and field screening in developed and developing markets alike. Consumer-Led Prevention Is Accelerating: Wearables and Bluetooth-enabled devices are empowering patients to engage in real-time health tracking and preventive care. Solving Market Uncertainty for Diagnostics Stakeholders The report helps product developers, investors, and strategic planners navigate today's diagnostics landscape by answering: Where are POC markets growing fastest by region and test category? How are pricing pressures and post-COVID shifts impacting product demand? What new technologies are redefining diagnostic accessibility and accuracy? How are regulatory frameworks influencing go-to-market strategies? "Abbott leads the market with more than 25% share through the strength of its diverse POC segment portfolio, with tests that include blood and electrolyte testing, cardiac markers, drugs of abuse, infectious diseases, and lipid testing. Companies like Dexcom and Roche continue to solidify their positions in areas such as continuous glucose monitoring and coagulation testing. While Exact Sciences' strength lies in growth in the colon cancer testing segment," said Elder. "Danaher, through Beckman Coulter, also plays a pivotal role in blood, cancer, and infectious disease diagnostics." An Essential Resource for Diagnostics Strategy The 12th edition of this flagship report includes: Market size and forecast through 2029 Enhanced segmentation across 10+ test types Analysis by venue (hospitals, clinics, retail, home) Competitive profiles and regulatory trend insights Developed by Kalorama Information's expert diagnostics analysts with over 25 years of combined experience, the report is based on extensive primary and secondary research. Get the Report "Worldwide Market for Point-of-Care Diagnostic Tests, 12th Edition" is available now at: For purchase or custom consultation, contact:Sheri DavieKalorama Information Sales For all other inquiries contact:Alisa AlvichMarketing About Kalorama InformationKalorama Information, a division of Science and Medicine Group, is a leading independent market research publisher in medical diagnostics, biotechnology, and life sciences. Our in-depth reports offer actionable insights to support critical business decisions for healthcare companies, investors, and institutions worldwide. View original content to download multimedia: SOURCE Kalorama Information Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
27-05-2025
- Business
- Yahoo
GlucoGuard a Division of American Diversified Holdings (ADHC) Successfully Submits Level 2 App Integration Through Dexcom's Developer Partner Program
Del Mar, California--(Newsfile Corp. - May 27, 2025) - American Diversified Holdings Corporation (OTC Pink: ADHC) announced today that GlucoGuard has completed the Level 2 App integration through DEXCOM's Developer Program. The project development is in conjunction with UC Irvine's MADO program through the California Institute for Telecommunications and Information Technology (CALIT2a). The Dexcom Developer Program is a partnership program that allows developers to access Dexcom API and integrate Dexcom CGM data into their own applications. Dexcom partners with the company to gain access to app credentials, sand box data, and development support. The Dexcom API allows partners to integrate DEXCOM CGM Data, such as glucose levels, into their applications. It is expected that in mid-June the next level of App integration development will be approved resulting in a fully functional back-end to front-end completion where the app will run on a mobile device. Developments Include: A functional front-end and back-end App capable of running on an emulator. A trained predictive algorithm for detecting hypoglycemia episodes with 95% accuracy. Secured Registered Developer access to the Dexcom API, enabling initial integration with continuous glucose monitoring (CGM) data. GlucoGuard is also developing a suite of AI features designed to predict negative blood glucose events and mitigate these events before the patient suffers catastrophic adverse effects. The ability to manage glucose in this manner is a groundbreaking advancement that will truly establish GlucoGuard as a revolutionary technology in the field of diabetes – a multibillion-dollar industry. "We are very appreciative to all our partners in reaching these milestones," commented ADHC. "Developments are progressing rapidly and the GlucoGuard team is very grateful for the amazing support from all of our stakeholders." ABOUT GLUCOGUARD GlucoGuardTo view an enhanced version of this graphic, please visit: ADHC is a medical device company developing GlucoGuard, a patent-pending nocturnal glucose monitoring and delivery system for diabetic patients. The system helps prevent the dangerous effects of hypoglycemia "low blood sugar" during sleep, including the potentially fatal "Death in Bed" phenomenon. Collaborating with a leading U.S. research university, a prominent biomedical engineering firm, and a major CGM company, GlucoGuard is at the forefront of diabetes management technology. GlucoGuard combines advanced engineering, artificial intelligence (AI), and mobile app-based monitoring to create an innovative solution for managing nocturnal Hypoglycemia. The GlucoGuard mouthpiece continuously monitors glucose levels during sleep and automatically administers glucose when hypoglycemic levels are detected. Sophisticated AI algorithms facilitate this process, ensuring effective glucose management without disturbing the patient's rest. ABOUT ARETE BIOSCIENCES, Inc. Arete To view an enhanced version of this graphic, please visit: Arete BioSciences, Inc. ("Arete") is a contact service organization with expertise in the design and development of early-stage medical technologies. Arete maintains an extensive network of internal staff and collaborators with experience across device form factor exploration, rapid prototyping, and product visualization in the health space. Arete BioScience includes a team of scientists, strategic thinkers, problem solvers, engineers, and innovators passionate about creating a positive impact on global health. Projects include the design, development, and management of molecular diagnostic systems, molecular assays, start-ups, and build-ups of several companies, and have managed product development teams across four continents in seven countries. ABOUT UCI CALIT 2 UCI CALIT2 To view an enhanced version of this graphic, please visit: Created in 2000, the California Institute for Telecommunications and Information Technology – known as CALIT2 – is one of four Gray Davis Institutes for Science and Innovation located on University of California campuses. The founding objective of CALIT2 was to create a world-class multidisciplinary research institute to promote discovery and innovation, notably to harness the ubiquity and scale of the internet and wireless technologies to accelerate growth in many different scientific areas and industries that are undergoing a massive transformation. Over two decades, CALIT2 has focused on transdisciplinary approaches of significant scale and complexity, as well as the creation of new, advanced scientific facilities, technical staff opportunities, and centers and 'living laboratories' to attract and support the nearly 250 UCI faculty who have opted to affiliate with the institute ABOUT DEXCOM Dexcom To view an enhanced version of this graphic, please visit: Dexcom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Stelo, a new over-the-counter glucose biosensor designed for adults with prediabetes and Type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California. COMPANY OVERVIEW Key Development PartnershipsThe GlucoGuard system is being developed in collaboration with three key partners: A leading U.S. research university, UNIVERSITY OF CALIFORNIA IRVINE. A highly respected biomedical engineering firm, ARETE BIOSCIENCE. A top publicly traded company in the Continuous Glucose Monitoring (CGM) sector DEXCOM. Further details on these collaborations will be disclosed soon. CUTTING-EDGE TECHNOLOGY FOR UNMET MEDICAL NEEDSGlucoGuard combines advanced engineering, artificial intelligence (AI), and mobile app-based monitoring to create an innovative solution for managing nocturnal hypoglycemia. The GlucoGuard mouthpiece continuously monitors glucose levels during sleep and automatically administers glucose when hypoglycemic levels are detected. Sophisticated AI algorithms facilitate this process, ensuring effective glucose management without disturbing the patient's rest. ABOUT ARTIFICIAL INTELLIGENCE AND HEALTHCAREA recent report from the Mayo Clinic identified three potential benefits of AI in healthcare: Improving outcomes for both patients and clinical teams Lowering healthcare costs Benefitting population health From preventive screenings to diagnosis and treatment, AI is being used throughout the continuum of care today. Two examples are Preventive Health Care and Risk Assessment. Cancer Screenings that use radiology can leverage AI to help produce results faster. A noted example is analyzing kidney images in a laborious 45-minute process. AI automated process can reduce this analysis to minutes, saving time, money and giving a more accurate diagnosis. Pre-diabetes patients with no notable symptoms can be screened using AI to determine which type of diabetes they are at risk for and begin preventative care. See AI in healthcare: The future of patient care and health management - Mayo Clinic Press. ABOUT THE DIABETES MARKETThe diabetes market is poised for substantial growth, with the U.S. market valued at $28 billion, underscoring the vast potential for GlucoGuard's adoption. For more information on the $28 billion diabetes market, visit: United States Diabetes Market Report. The Continuous Glucose Monitoring (CGM) sector, valued at $6.8 billion, further emphasizes the critical demand for advanced glucose management solutions. For details on the CGM market, visit: Continuous Glucose Monitoring Market. Image 1 To view an enhanced version of this graphic, please visit: ABOUT GLUCOGUARDGlucoGuard, a Division of American Diversified Holdings Corporation is a patent-pending nocturnal glucose monitoring and delivery system for diabetic patients. The system helps prevent the dangerous effects of low blood sugar during sleep, including the potentially fatal "Death in Bed" phenomenon. Collaborating with a leading U.S. research university, a prominent biomedical engineering firm, and a major CGM company, GlucoGuard is at the forefront of diabetes management technology. For more information, visit: Phone: 817-525-0057Email: info@ Image 2 To view an enhanced version of this graphic, please visit: ABOUT AMERICAN DIVERSIFIED HOLDINGS CORPORATION John Cacchioli, CEOAmerican Diversified Holdings CorporationTelephone: (212) 537-5900 INVESTOR HOTLINE 858-325-7098Email: JC@ ADHCInvestor@ SOCIAL MEDIATWITTER: @ Twitter page is the only official Twitter page for ADHC. SAFE HARBOR FORWARD-LOOKING STATEMENTS: This press release may contain forward-looking statements that are based on current expectations, forecasts, and assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected, including statements related to the amount and timing of expected revenues related to our financial performance, expected revenue, contracts, and future growth for upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC) and on the OTC Disclosure & News Service (OTCDNS). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in our filings with the SEC and/or OTCDNS. Among other matters, the Company may not be able to sustain growth or achieve profitability based upon many factors including but not limited to the risk that we will not be able to find and secure construction contracts and the necessary assets that will enable us to become profitable. Reference is hereby made to cautionary statements set forth in the Company's most recent SEC and/or OTCDNS filings. We have incurred and will continue to incur significant expenses in our development stage, noting that there is no assurance that we will generate enough revenues to offset those costs in both the near and long term. New lines of business in the construction industry may expose us to additional legal and regulatory costs and unknown exposure(s), the impact of which cannot be predicted at this time. Words such as "estimate," "project," "predict," "will," "would," "should," "could," "may," "might," "anticipate," "plan," "intend," "believe," "expect," "aim," "goal," "target," "objective," "likely" or similar expressions that convey the prospective nature of events or outcomes generally indicate forward-looking statements. You should not place undue reliance on these forward-looking statements, which speak only as of this press release. Unless legally required, we undertake no obligation to update, modify or withdraw any forward-looking statements, because of new information, future events or otherwise. To view the source version of this press release, please visit
